List view / Grid view
A novel all-optical system uses optogenetics, machine vision cameras, and off-the-shelf components to stimulate and image engineered networks of human heart cells.
A new AI model can accelerate drug discovery by accurately predicting human response to novel drug compounds.
A newly developed AAV has shown promise at delivering gene therapies to the brain in mice and non-human primates.
Join leading experts as they discuss the wide range of uses for CRISPR, including for therapeutics and biomanufacturing.
Scientists have published a report on the whole genome sequences of 150 thousand participants in the UK biobank.
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
Researchers have developed a promising new tool that accurately uses genomic data to predict disease risk across diverse populations.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
The capability to edit genes has been transformative in opening therapeutic avenues for hitherto untreatable diseases and aiding biological insight. Scientists have now discovered a way to enhance this process using retrons, making the process more efficient and effective.
4 January 2022 | By SomaLogic
Watch our on-demand one-hour session to discover groundbreaking work to advance precision medicine for Castleman disease.
Scientists have developed a metal-organic framework that, when attached to antibodies, improved their targeted delivery in in vitro studies.
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
Researchers discover a new precision strategy to hinder the infection of the coronavirus, leading to the filing of a new drug patent.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
The new findings suggest that inhibiting p53 can reduce CRISPR-associated cancer risks and may lead to developments in precision medicine.
